Abbott Plans R&D, Marketing Investments For i-STAT Following Acquisition
This article was originally published in The Gray Sheet
Executive Summary
i-STAT will be assured access to Abbott's brain natriuretic peptide (BNP) marker to develop a point-of-care myocardial infarction diagnostic if a proposed $392 mil. merger is approved by i-STAT shareholders